SG11201510601TA - Antibody formulations and methods - Google Patents
Antibody formulations and methodsInfo
- Publication number
- SG11201510601TA SG11201510601TA SG11201510601TA SG11201510601TA SG11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- antibody formulations
- antibody
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361843011P | 2013-07-04 | 2013-07-04 | |
US201461979886P | 2014-04-15 | 2014-04-15 | |
PCT/IB2014/062806 WO2015001504A2 (en) | 2013-07-04 | 2014-07-03 | Antibody formulations and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201510601TA true SG11201510601TA (en) | 2016-01-28 |
Family
ID=51355583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201510601TA SG11201510601TA (en) | 2013-07-04 | 2014-07-03 | Antibody formulations and methods |
Country Status (18)
Country | Link |
---|---|
US (2) | US10513555B2 (es) |
EP (2) | EP3016677B1 (es) |
JP (3) | JP6404338B2 (es) |
KR (1) | KR20160030247A (es) |
CN (1) | CN105492019B (es) |
AU (1) | AU2014285719A1 (es) |
CA (1) | CA2917097C (es) |
CL (1) | CL2015003801A1 (es) |
CU (2) | CU20170039A7 (es) |
ES (1) | ES2704440T3 (es) |
HK (1) | HK1223544A1 (es) |
IL (1) | IL243425A0 (es) |
MX (1) | MX2016000201A (es) |
PE (1) | PE20160868A1 (es) |
PH (1) | PH12015502788A1 (es) |
RU (1) | RU2016103079A (es) |
SG (1) | SG11201510601TA (es) |
WO (1) | WO2015001504A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA116194C2 (uk) | 2011-10-28 | 2018-02-26 | Протена Біосаєнсиз Лімітед | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном |
ES2749457T3 (es) | 2012-01-27 | 2020-03-20 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen la alfa-sinucleína |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
LT3334747T (lt) | 2015-08-13 | 2023-12-27 | Amgen Inc. | Įkrautas giluminis antigeną surišančio baltymo filtravimas |
KR20180054791A (ko) * | 2015-09-28 | 2018-05-24 | 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 | 안정한 항-pd-1 항체 약학적 제조물 및 의료에서의 그의 적용 |
CN105127166A (zh) * | 2015-09-29 | 2015-12-09 | 中国华能集团清洁能源技术研究院有限公司 | 行走组件及具有其的光伏组件清洁装置 |
RS62035B1 (sr) * | 2016-06-27 | 2021-07-30 | Morphosys Ag | Formulacije anti-cd19 antitela |
BR112018014281A2 (pt) * | 2016-11-15 | 2018-12-18 | H Lundbeck As | agentes, usos e métodos para o tratamento da sinucleinopatia |
BR112018016717A2 (pt) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agentes, usos e métodos |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
JP2021502955A (ja) * | 2017-09-28 | 2021-02-04 | プロセナ・バイオサイエンシズ・リミテッド | シヌクレイン病の治療のための投与レジメン |
US20190153102A1 (en) * | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
JP6831861B2 (ja) | 2019-01-25 | 2021-02-17 | 株式会社Grin | 歯科用測定器具、測定方法、及びアタッチメント器具 |
CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
EP3786174A1 (en) * | 2019-08-27 | 2021-03-03 | Ichnos Sciences SA | Methods for antibody purification |
GB2587228B (en) * | 2019-09-20 | 2021-10-27 | Protein Ark Ltd | Biological sample purification apparatus, use of the same, and systems comprising the same |
WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
KR20240055758A (ko) * | 2021-09-16 | 2024-04-29 | 하. 룬드벡 아크티에셀스카브 | 시누클레인병증을 치료하기 위한 조성물 및 방법 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AU695129B2 (en) | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
SG142124A1 (en) | 1999-02-05 | 2008-05-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
BR0309093A (pt) | 2002-04-09 | 2005-02-09 | Flamel Tech Sa | Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina |
CA2485342A1 (en) | 2002-05-13 | 2004-05-13 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
ES2293096T3 (es) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
DK2335725T3 (en) | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DK1820022T3 (da) | 2004-11-10 | 2009-09-14 | Boehringer Ingelheim Pharma | Anvendelse af flow-cytometrisk analyse for at optimere cellebanks-strategier af CHO-celler |
WO2007011907A2 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
AU2006329963B2 (en) * | 2005-12-06 | 2011-06-09 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2126093B1 (en) | 2007-03-02 | 2012-10-10 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
RU2500686C2 (ru) | 2007-03-22 | 2013-12-10 | Дженентек, Инк. | АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE |
MX2009010179A (es) * | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
US9308257B2 (en) * | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
PT2234600E (pt) | 2007-12-21 | 2014-09-25 | Hoffmann La Roche | Formulação de anticorpos |
EP2730659A3 (en) | 2007-12-28 | 2016-01-13 | Prothena Biosciences Limited | Treatment and Prophylaxis of Amyloidosis |
LT2282758T (lt) | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
ES2544569T3 (es) | 2008-12-19 | 2015-09-01 | Biogen International Neuroscience Gmbh | Autoanticuerpos humanos anti alfa-sinucleina |
CN109172813B (zh) | 2009-07-28 | 2022-09-02 | 武田药品工业株式会社 | 用于治疗戈谢病的组合物和方法 |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
US9028830B2 (en) | 2010-04-08 | 2015-05-12 | JN Biosciences, LLC | Antibodies to CD122 |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
JP5886283B2 (ja) | 2010-07-15 | 2016-03-16 | アドヘロン セラピューティクス,インコーポレイテッド | カドヘリン−11のec1ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
EP2627425A4 (en) * | 2010-10-11 | 2014-11-05 | Abbvie Inc | METHODS OF PURIFYING PROTEINS |
CA2825791A1 (en) | 2011-02-07 | 2012-08-16 | Neotope Biosciences Limited | Apoe immunotherapy |
WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
EP2726098A1 (en) * | 2011-06-30 | 2014-05-07 | F.Hoffmann-La Roche Ag | Anti-c-met antibody formulations |
PE20191242A1 (es) * | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | Formulaciones de anticuerpo y metodos |
UA116194C2 (uk) | 2011-10-28 | 2018-02-26 | Протена Біосаєнсиз Лімітед | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном |
KR20140084078A (ko) | 2011-10-31 | 2014-07-04 | 제넨테크, 인크. | 항체 제제 |
ES2749457T3 (es) | 2012-01-27 | 2020-03-20 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen la alfa-sinucleína |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
SI2890712T1 (sl) | 2012-08-29 | 2019-08-30 | F. Hoffmann-La Roche Ag | Prenašalec prek krvno-možganske pregrade |
US8925815B2 (en) | 2012-09-05 | 2015-01-06 | Symbol Technologies, Inc. | Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2014
- 2014-07-02 US US14/322,797 patent/US10513555B2/en active Active
- 2014-07-03 ES ES14752412T patent/ES2704440T3/es active Active
- 2014-07-03 CU CUP2017000039A patent/CU20170039A7/es unknown
- 2014-07-03 CN CN201480047476.9A patent/CN105492019B/zh active Active
- 2014-07-03 AU AU2014285719A patent/AU2014285719A1/en not_active Abandoned
- 2014-07-03 WO PCT/IB2014/062806 patent/WO2015001504A2/en active Application Filing
- 2014-07-03 RU RU2016103079A patent/RU2016103079A/ru not_active Application Discontinuation
- 2014-07-03 KR KR1020167003163A patent/KR20160030247A/ko not_active Application Discontinuation
- 2014-07-03 MX MX2016000201A patent/MX2016000201A/es unknown
- 2014-07-03 JP JP2016522950A patent/JP6404338B2/ja active Active
- 2014-07-03 EP EP14752412.8A patent/EP3016677B1/en active Active
- 2014-07-03 EP EP18212531.0A patent/EP3524264A1/en active Pending
- 2014-07-03 PE PE2015002708A patent/PE20160868A1/es not_active Application Discontinuation
- 2014-07-03 SG SG11201510601TA patent/SG11201510601TA/en unknown
- 2014-07-03 CA CA2917097A patent/CA2917097C/en active Active
-
2015
- 2015-12-16 PH PH12015502788A patent/PH12015502788A1/en unknown
- 2015-12-31 CL CL2015003801A patent/CL2015003801A1/es unknown
- 2015-12-31 IL IL243425A patent/IL243425A0/en unknown
-
2016
- 2016-01-04 CU CUP2016000001A patent/CU20160001A7/es unknown
- 2016-10-12 HK HK16111756.3A patent/HK1223544A1/zh unknown
-
2018
- 2018-09-12 JP JP2018170393A patent/JP6854266B2/ja active Active
-
2019
- 2019-11-01 US US16/672,330 patent/US20200140534A1/en not_active Abandoned
-
2020
- 2020-10-23 JP JP2020177954A patent/JP2021020941A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105492019B (zh) | 2020-02-11 |
PH12015502788A1 (en) | 2016-03-21 |
MX2016000201A (es) | 2016-05-31 |
PE20160868A1 (es) | 2016-09-24 |
CA2917097A1 (en) | 2015-01-08 |
EP3016677A2 (en) | 2016-05-11 |
WO2015001504A2 (en) | 2015-01-08 |
JP2021020941A (ja) | 2021-02-18 |
US20200140534A1 (en) | 2020-05-07 |
JP2019011339A (ja) | 2019-01-24 |
CN105492019A (zh) | 2016-04-13 |
HK1223544A1 (zh) | 2017-08-04 |
EP3016677B1 (en) | 2018-12-19 |
JP6404338B2 (ja) | 2018-10-10 |
AU2014285719A1 (en) | 2016-01-21 |
JP2016534052A (ja) | 2016-11-04 |
RU2016103079A (ru) | 2017-08-07 |
CU20170039A7 (es) | 2017-06-05 |
US10513555B2 (en) | 2019-12-24 |
WO2015001504A3 (en) | 2015-08-06 |
CA2917097C (en) | 2022-05-03 |
EP3524264A1 (en) | 2019-08-14 |
JP6854266B2 (ja) | 2021-04-07 |
ES2704440T3 (es) | 2019-03-18 |
KR20160030247A (ko) | 2016-03-16 |
CL2015003801A1 (es) | 2016-07-15 |
CU20160001A7 (es) | 2016-08-31 |
IL243425A0 (en) | 2016-03-31 |
US20150079074A1 (en) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261743B (en) | and their uses 33–il antibodies against | |
HK1223544A1 (zh) | 抗體製劑和方法 | |
ZA202005525B (en) | Antibody formulations | |
HK1232243A1 (zh) | 抗- 抗體及其用途 | |
IL261547B (en) | Antibodies against pesidine and their uses | |
IL244712B (en) | Anti- pdl1 antibody compositions | |
IL245040B (en) | Antibodies against pdgfr-beta and their uses | |
IL243974B (en) | Antibodies against –prlr and uses | |
IL240517A0 (en) | Antibodies against b7–h4 and immunoconjugates | |
SG10201708143QA (en) | Anti-c10orf54 antibodies and uses thereof | |
SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof |